{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T12:29:42Z","timestamp":1790166582366,"version":"4.1.0"},"reference-count":77,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,3,2]],"date-time":"2021-03-02T00:00:00Z","timestamp":1614643200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,3,2]],"date-time":"2021-03-02T00:00:00Z","timestamp":1614643200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100006492","name":"Division of Intramural Research, National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006492","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Vaccines"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Lassa virus (LASV) infects hundreds of thousands of individuals each year, highlighting the need for the accelerated development of preventive, diagnostic, and therapeutic interventions. To date, no vaccine has been licensed for LASV. ChAdOx1-Lassa-GPC is a chimpanzee adenovirus-vectored vaccine encoding the Josiah strain LASV glycoprotein precursor (GPC) gene. In the following study, we show that ChAdOx1-Lassa-GPC is immunogenic, inducing robust T-cell and antibody responses in mice. Furthermore, a single dose of ChAdOx1-Lassa-GPC fully protects Hartley guinea pigs against morbidity and mortality following lethal challenge with a guinea pig-adapted LASV (strain Josiah). By contrast, control vaccinated animals reached euthanasia criteria 10\u201312 days after infection. Limited amounts of LASV RNA were detected in the tissues of vaccinated animals. Viable LASV was detected in only one animal receiving a single dose of the vaccine. A prime-boost regimen of ChAdOx1-Lassa-GPC in guinea pigs significantly increased antigen-specific antibody titers and cleared viable LASV from the tissues. These data support further development of ChAdOx1-Lassa-GPC and testing in non-human primate models of infection.<\/jats:p>","DOI":"10.1038\/s41541-021-00291-x","type":"journal-article","created":{"date-parts":[[2021,3,2]],"date-time":"2021-03-02T11:04:56Z","timestamp":1614683096000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":52,"title":["ChAdOx1-vectored Lassa fever vaccine elicits a robust cellular and humoral immune response and protects guinea pigs against lethal Lassa virus challenge"],"prefix":"10.1038","volume":"6","author":[{"given":"Robert J.","family":"Fischer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6190-4199","authenticated-orcid":false,"given":"Jyothi N.","family":"Purushotham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4368-6359","authenticated-orcid":false,"given":"Neeltje","family":"van Doremalen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Sebastian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly","family":"Meade-White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"Cordova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Letko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Jeremiah Matson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Friederike","family":"Feldmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaine","family":"Haddock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"LaCasse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Greg","family":"Saturday","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7711-897X","authenticated-orcid":false,"given":"Teresa","family":"Lambe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6823-9750","authenticated-orcid":false,"given":"Sarah C.","family":"Gilbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2288-3196","authenticated-orcid":false,"given":"Vincent J.","family":"Munster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,3,2]]},"reference":[{"key":"291_CR1","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1136\/bmj.327.7426.1271","volume":"327","author":"JK Richmond","year":"2003","unstructured":"Richmond, J. K. & Baglole, D. J. Clinical review Lassa fever: epidemiology, clinical features, and social consequences. Br. Med. J. 327, 1271\u20131275 (2003).","journal-title":"Br. Med. J."},{"key":"291_CR2","doi-asserted-by":"crossref","unstructured":"Bowen, M. D. et al. Genetic diversity among Lassa virus strains. J. Virol. 74, 6992\u20137004 (2000).","DOI":"10.1128\/JVI.74.15.6992-7004.2000"},{"key":"291_CR3","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.3201\/eid1607.100146","volume":"16","author":"D Safronetz","year":"2010","unstructured":"Safronetz, D. et al. Detection of Lassa virus, Mali. Emerg. Infect. Dis. 16, 1123\u20131126 (2010).","journal-title":"Emerg. Infect. Dis."},{"key":"291_CR4","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.3201\/eid2108.150312","volume":"21","author":"L Kouadio","year":"2015","unstructured":"Kouadio, L. et al. Lassa virus in multimammate rats, C\u00f4te d\u2019Ivoire, 2013. Emerg. Infect. Dis. 21, 1481\u20131483 (2015).","journal-title":"Emerg. Infect. Dis."},{"key":"291_CR5","doi-asserted-by":"publisher","first-page":"599","DOI":"10.3201\/eid2403.171905","volume":"24","author":"SLM Whitmer","year":"2018","unstructured":"Whitmer, S. L. M. et al. New lineage of Lassa virus, Togo, 2016. Emerg. Infect. Dis. 24, 599\u2013602 (2018).","journal-title":"Emerg. Infect. Dis."},{"key":"291_CR6","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1126\/science.185.4147.263","volume":"185","author":"TP Monath","year":"1974","unstructured":"Monath, T. P., Newhouse, V. F., Kemp, G. E., Setzer, H. W. & Cacciapuoti, A. Lassa virus isolation from Mastomys natalensis rodents during an epidemic in Sierra Leone. Science 185, 263\u2013265 (1974).","journal-title":"Science"},{"key":"291_CR7","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.3201\/eid1212.060812","volume":"12","author":"E Lecompte","year":"2006","unstructured":"Lecompte, E. et al. Mastomys natalensis and Lassa fever, West Africa. Emerg. Infect. Dis. 12, 1971\u20131974 (2006).","journal-title":"Emerg. Infect. Dis."},{"key":"291_CR8","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1136\/bmj.311.7009.857","volume":"311","author":"SP Fisher-Hoch","year":"1995","unstructured":"Fisher-Hoch, S. P. et al. Review of cases of nosocomial Lassa fever in Nigeria: the high price of poor medical practice. BMJ 311, 857\u2013859 (1995).","journal-title":"BMJ"},{"key":"291_CR9","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.ijid.2019.03.030","volume":"83","author":"CC Dan-Nwafor","year":"2019","unstructured":"Dan-Nwafor, C. C. et al. A cluster of nosocomial Lassa fever cases in a tertiary health facility in Nigeria: description and lessons learned, 2018. Int. J. Infect. Dis. 83, 88\u201394 (2019).","journal-title":"Int. J. Infect. Dis."},{"key":"291_CR10","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1093\/infdis\/155.3.437","volume":"155","author":"JB McCormick","year":"1987","unstructured":"McCormick, J. B., Webb, P. A., Krebs, J. W., Johnson, K. M. & Smith, E. S. A prospective study of the epidemiology and ecology of Lassa fever. J. Infect. Dis. 155, 437\u2013444 (1987).","journal-title":"J. Infect. Dis."},{"key":"291_CR11","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1080\/20477724.2017.1369643","volume":"111","author":"R Gibb","year":"2017","unstructured":"Gibb, R., Moses, L. M., Redding, D. W. & Jones, K. E. Understanding the cryptic nature of Lassa fever in West Africa. Pathog. Glob. Health 111, 276\u2013288 (2017).","journal-title":"Pathog. Glob. Health"},{"key":"291_CR12","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1093\/infdis\/155.3.445","volume":"155","author":"JB McCormick","year":"1987","unstructured":"McCormick, J. B. et al. A case-control study of the clinical diagnosis and course of Lassa fever. J. Infect. Dis. 155, 445\u2013455 (1987).","journal-title":"J. Infect. Dis."},{"key":"291_CR13","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0002748","volume":"8","author":"JG Shaffer","year":"2014","unstructured":"Shaffer, J. G. et al. Lassa fever in post-conflict Sierra Leone. PLoS Negl. Trop. Dis. 8, e2748 (2014).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"291_CR14","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1016\/S1473-3099(18)30121-X","volume":"18","author":"P Okokhere","year":"2018","unstructured":"Okokhere, P. et al. Clinical and laboratory predictors of Lassa fever outcome in a dedicated treatment facility in Nigeria: a retrospective, observational cohort study. Lancet Infect. Dis. 18, 684\u2013695 (2018).","journal-title":"Lancet Infect. Dis."},{"key":"291_CR15","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1136\/bmj.297.6648.584","volume":"297","author":"ME Price","year":"1988","unstructured":"Price, M. E., Fisher-Hoch, S. P., Craven, R. B. & McCormick, J. B. A prospective study of maternal and fetal outcome in acute Lassa fever infection during pregnancy. Br. Med. J. 297, 584\u2013587 (1988).","journal-title":"Br. Med. J."},{"key":"291_CR16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1743-422X-8-1","volume":"8","author":"LM Branco","year":"2011","unstructured":"Branco, L. M. et al. Lassa hemorrhagic fever in a late term pregnancy from northern Sierra Leone with a positive maternal outcome: Case report. Virol. J. 8, 1\u201314 (2011).","journal-title":"Virol. J."},{"key":"291_CR17","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1001\/jama.1990.03450160063030","volume":"264","author":"D Cummins","year":"1990","unstructured":"Cummins, D. et al. Acute sensorineural deafness in Lassa fever. JAMA 264, 2093\u20132096 (1990).","journal-title":"JAMA"},{"key":"291_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pntd.0006187","volume":"12","author":"EJ Mateer","year":"2018","unstructured":"Mateer, E. J., Huang, C., Shehu, N. Y. & Paessler, S. Lassa fever\u2013induced sensorineural hearing loss: A neglected public health and social burden. PLoS Negl. Trop. Dis. 12, 1\u201311 (2018).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"291_CR19","doi-asserted-by":"publisher","first-page":"e00929","DOI":"10.1128\/JVI.00929-19","volume":"93","author":"DU Ehichioya","year":"2019","unstructured":"Ehichioya, D. U. et al. Phylogeography of Lassa virus in Nigeria. J. Virol. 93, e00929\u201319 (2019).","journal-title":"J. Virol."},{"key":"291_CR20","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1056\/NEJMoa1804498","volume":"379","author":"KJ Siddle","year":"2018","unstructured":"Siddle, K. J. et al. Genomic analysis of Lassa virus during an increase in cases in Nigeria in 2018. N. Engl. J. Med. 379, 1745\u20131753 (2018).","journal-title":"N. Engl. J. Med."},{"key":"291_CR21","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1126\/science.aau9343","volume":"363","author":"LE Kafetzopoulou","year":"2019","unstructured":"Kafetzopoulou, L. E. et al. Metagenomic sequencing at the epicenter of the Nigeria 2018 Lassa fever outbreak. Science 363, 74\u201377 (2019).","journal-title":"Science"},{"key":"291_CR22","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.3389\/fmicb.2015.01037","volume":"6","author":"JT Manning","year":"2015","unstructured":"Manning, J. T., Forrester, N. & Paessler, S. Lassa virus isolates from Mali and the Ivory Coast represent an emerging fifth lineage. Front. Microbiol 6, 1037 (2015).","journal-title":"Front. Microbiol"},{"key":"291_CR23","doi-asserted-by":"publisher","first-page":"25280","DOI":"10.1038\/srep25280","volume":"6","author":"A Olayemi","year":"2016","unstructured":"Olayemi, A. et al. New hosts of the Lassa virus. Sci. Rep. 6, 25280 (2016).","journal-title":"Sci. Rep."},{"key":"291_CR24","doi-asserted-by":"publisher","first-page":"2902","DOI":"10.1080\/21645515.2017.1356500","volume":"13","author":"KA Cashman","year":"2017","unstructured":"Cashman, K. A. et al. A DNA vaccine delivered by dermal electroporation fully protects cynomolgus macaques against Lassa fever. Hum. Vaccin. Immunother. 13, 2902\u20132911 (2017).","journal-title":"Hum. Vaccin. Immunother."},{"key":"291_CR25","doi-asserted-by":"publisher","first-page":"e00039","DOI":"10.1128\/mBio.00039-20","volume":"11","author":"Y Cai","year":"2020","unstructured":"Cai, Y. et al. A Lassa fever live-attenuated vaccine based on codon deoptimization of the viral glycoprotein gene. MBio 11, e00039\u201320 (2020).","journal-title":"MBio"},{"key":"291_CR26","doi-asserted-by":"publisher","first-page":"5246","DOI":"10.1016\/j.vaccine.2008.07.057","volume":"26","author":"IS Lukashevich","year":"2008","unstructured":"Lukashevich, I. S. et al. Safety, immunogenicity, and efficacy of the ML29 reassortant vaccine for Lassa fever in small non-human primates. Vaccine 26, 5246\u20135254 (2008).","journal-title":"Vaccine"},{"key":"291_CR27","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0020183","volume":"2","author":"TW Geisbert","year":"2005","unstructured":"Geisbert, T. W. et al. Development of a new vaccine for the prevention of Lassa fever. PLoS Med. 2, e183 (2005).","journal-title":"PLoS Med."},{"key":"291_CR28","doi-asserted-by":"publisher","first-page":"1957","DOI":"10.1093\/infdis\/jiy123","volume":"217","author":"MH Kainulainen","year":"2018","unstructured":"Kainulainen, M. H. et al. Use of a scalable replicon-particle vaccine to protect against lethal Lassa virus infection in the guinea pig model. J. Infect. Dis. 217, 1957\u20131966 (2018).","journal-title":"J. Infect. Dis."},{"key":"291_CR29","doi-asserted-by":"publisher","first-page":"4223","DOI":"10.1038\/s41467-018-06741-w","volume":"9","author":"T Abreu-Mota","year":"2018","unstructured":"Abreu-Mota, T. et al. Non-neutralizing antibodies elicited by recombinant Lassa-rabies vaccine are critical for protection against Lassa fever. Nat. Commun. 9, 4223 (2018).","journal-title":"Nat. Commun."},{"key":"291_CR30","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.virol.2005.12.001","volume":"345","author":"PJ Bredenbeek","year":"2006","unstructured":"Bredenbeek, P. J. et al. A recombinant yellow fever 17D vaccine expressing Lassa virus glycoproteins. Virology 345, 299\u2013304 (2006).","journal-title":"Virology"},{"key":"291_CR31","doi-asserted-by":"publisher","first-page":"11677","DOI":"10.1128\/JVI.75.23.11677-11685.2001","volume":"75","author":"P Pushko","year":"2001","unstructured":"Pushko, P., Geisbert, J., Parker, M., Jahrling, P. & Smith, J. Individual and bivalent vaccines based on alphavirus replicons protect guinea pigs against infection with Lassa and Ebola viruses. J. Virol. 75, 11677\u201311685 (2001).","journal-title":"J. Virol."},{"key":"291_CR32","doi-asserted-by":"crossref","unstructured":"Mateo, M. et al. Vaccines inducing immunity to Lassa virus glycoprotein and nucleoprotein protect macaques after a single shot. Sci. Transl. Med. 11, eaaw3163 (2019).","DOI":"10.1126\/scitranslmed.aaw3163"},{"key":"291_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-017-0029-1","volume":"2","author":"VJ Munster","year":"2017","unstructured":"Munster, V. J. et al. Protective efficacy of a novel simian adenovirus vaccine against lethal MERS-CoV challenge in a transgenic human DPP4 mouse model. npj Vaccines 2, 28 (2017).","journal-title":"npj Vaccines"},{"key":"291_CR34","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1186\/1743-422X-10-349","volume":"10","author":"GM Warimwe","year":"2013","unstructured":"Warimwe, G. M. et al. Immunogenicity and efficacy of a chimpanzee adenovirus-vectored Rift Valley fever vaccine in mice. Virol. J. 10, 349 (2013).","journal-title":"Virol. J."},{"key":"291_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/srep20617","volume":"6","author":"GM Warimwe","year":"2016","unstructured":"Warimwe, G. M. et al. Chimpanzee adenovirus vaccine provides multispecies protection against Rift Valley Fever. Sci. Rep. 6, 20617 (2016).","journal-title":"Sci. Rep."},{"key":"291_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-04859-5","volume":"9","author":"C Lopez-Camacho","year":"2018","unstructured":"Lopez-Camacho, C. et al. Rational Zika vaccine design via the modulation of antigen membrane anchors in chimpanzee adenoviral vectors. Nat. Commun. 9, 2441 (2018).","journal-title":"Nat. Commun."},{"key":"291_CR37","doi-asserted-by":"crossref","unstructured":"Stylianou, E. et al. Identification and evaluation of novel protective antigens for the development of a candidate tuberculosis subunit vaccine. Infect. Immun. 86, e00014-18 (2018).","DOI":"10.1128\/IAI.00014-18"},{"key":"291_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/srep14775","volume":"5","author":"D Safronetz","year":"2015","unstructured":"Safronetz, D. et al. The broad-spectrum antiviral favipiravir protects guinea pigs from lethal Lassa virus infection post-disease onset. Sci. Rep. 5, 14775 (2015).","journal-title":"Sci. Rep."},{"key":"291_CR39","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1093\/infdis\/155.3.456","volume":"155","author":"KM Johnson","year":"1987","unstructured":"Johnson, K. M. et al. Clinical virology of Lassa fever in hospitalized patients. J. Infect. Dis. 155, 456\u2013464 (1987).","journal-title":"J. Infect. Dis."},{"key":"291_CR40","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/BF02122441","volume":"175","author":"PB Jahrling","year":"1986","unstructured":"Jahrling, P. B. & Peters, C. J. Serology and virulence diversity among Old-World arenaviruses, and the relevance to vaccine development. Med. Microbiol. Immunol. 175, 165\u2013167 (1986).","journal-title":"Med. Microbiol. Immunol."},{"key":"291_CR41","doi-asserted-by":"publisher","first-page":"3497","DOI":"10.1128\/jvi.67.6.3497-3506.1993","volume":"67","author":"VJ La Posta","year":"1993","unstructured":"La Posta, V. J., Auperin, D. D., Kamin-Lewis, R. & Cole, G. A. Cross-protection against lymphocytic choriomeningitis virus mediated by a CD4+ T-cell clone specific for an envelope glycoprotein epitope of Lassa virus. J. Virol. 67, 3497\u20133506 (1993).","journal-title":"J. Virol."},{"key":"291_CR42","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1038\/mt.2012.25","volume":"20","author":"A Reyes-Sandoval","year":"2012","unstructured":"Reyes-Sandoval, A. et al. Mixed vector immunization with recombinant adenovirus and MVA can improve vaccine efficacy while decreasing antivector immunity. Mol. Ther. 20, 1633\u20131647 (2012).","journal-title":"Mol. Ther."},{"key":"291_CR43","doi-asserted-by":"publisher","first-page":"4955","DOI":"10.1016\/j.vaccine.2016.08.048","volume":"34","author":"P Penaloza-MacMaster","year":"2016","unstructured":"Penaloza-MacMaster, P. et al. Inhibitory receptor expression on memory CD8 T cells following Ad vector immunization. Vaccine 34, 4955\u20134963 (2016).","journal-title":"Vaccine"},{"key":"291_CR44","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1016\/j.cell.2015.07.020","volume":"162","author":"KG Andersen","year":"2015","unstructured":"Andersen, K. G. et al. Clinical sequencing uncovers origins and evolution of Lassa virus. Cell 162, 738\u2013750 (2015).","journal-title":"Cell"},{"key":"291_CR45","doi-asserted-by":"publisher","first-page":"11544","DOI":"10.1038\/ncomms11544","volume":"7","author":"JE Robinson","year":"2016","unstructured":"Robinson, J. E. Most neutralizing human monoclonal antibodies target novel epitopes requiring both Lassa virus glycoprotein subunits. Nat. Commun. 7, 11544 (2016).","journal-title":"Nat. Commun."},{"key":"291_CR46","unstructured":"WHO. WHO Target Product Profile For Lassa Virus Vaccine. https:\/\/www.who.int\/blueprint\/priority-diseases\/key-action\/LassaVirusVaccineTPP.PDF (2017)."},{"key":"291_CR47","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0040385","volume":"7","author":"MDJ Dicks","year":"2012","unstructured":"Dicks, M. D. J. et al. A novel chimpanzee adenovirus vector with low human seroprevalence: improved systems for vector derivation and comparative immunogenicity. PLoS ONE 7, e40385 (2012).","journal-title":"PLoS ONE"},{"key":"291_CR48","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1038\/mt.2013.284","volume":"22","author":"RD Antrobus","year":"2014","unstructured":"Antrobus, R. D. et al. Clinical assessment of a novel recombinant simian adenovirus ChAdOx1 as a vectored vaccine expressing conserved influenza A antigens. Mol. Ther. 22, 668\u2013674 (2014).","journal-title":"Mol. Ther."},{"key":"291_CR49","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.ebiom.2018.02.011","volume":"29","author":"L Coughlan","year":"2018","unstructured":"Coughlan, L. et al. Heterologous two-dose vaccination with simian adenovirus and poxvirus vectors elicits long-lasting cellular immunity to influenza virus A in healthy adults. EBioMedicine 29, 146\u2013154 (2018).","journal-title":"EBioMedicine"},{"key":"291_CR50","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1038\/mt.2016.83","volume":"24","author":"MO Afolabi","year":"2016","unstructured":"Afolabi, M. O. et al. Safety and immunogenicity of ChAd63 and MVA ME-TRAP in West African children and infants. Mol. Ther. J. Am. Soc. Gene Ther. 24, 1470\u20131477 (2016).","journal-title":"J. Am. Soc. Gene Ther."},{"key":"291_CR51","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.3389\/fimmu.2017.01551","volume":"8","author":"VA Mensah","year":"2017","unstructured":"Mensah, V. A. et al. Safety and immunogenicity of malaria vectored vaccines given with routine expanded program on immunization vaccines in Gambian infants and neonates: A randomized controlled trial. Front. Immunol. 8, 1551 (2017).","journal-title":"Front. Immunol."},{"key":"291_CR52","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/j.ymthe.2016.11.003","volume":"25","author":"CM Bliss","year":"2017","unstructured":"Bliss, C. M. et al. Viral vector malaria vaccines induce high-level T cell and antibody responses in West African children and infants. Mol. Ther. J. Am. Soc. Gene Ther. 25, 547\u2013559 (2017).","journal-title":"J. Am. Soc. Gene Ther."},{"key":"291_CR53","doi-asserted-by":"publisher","first-page":"2296","DOI":"10.1016\/j.vaccine.2016.03.061","volume":"34","author":"P Dulal","year":"2016","unstructured":"Dulal, P. et al. Potency of a thermostabilised chimpanzee adenovirus Rift Valley Fever vaccine in cattle. Vaccine 34, 2296\u20132298 (2016).","journal-title":"Vaccine"},{"key":"291_CR54","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0003736","volume":"9","author":"D Safronetz","year":"2015","unstructured":"Safronetz, D. et al. A recombinant vesicular stomatitis virus-based Lassa fever vaccine protects guinea pigs and macaques against challenge with geographically and genetically distinct Lassa viruses. PLoS Negl. Trop. Dis. 9, e0003736 (2015).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"291_CR55","doi-asserted-by":"publisher","first-page":"4093","DOI":"10.1016\/j.vaccine.2007.02.038","volume":"25","author":"RJ Carrion","year":"2007","unstructured":"Carrion, R. J. et al. A ML29 reassortant virus protects guinea pigs against a distantly related Nigerian strain of Lassa virus and can provide sterilizing immunity. Vaccine 25, 4093\u20134102 (2007).","journal-title":"Vaccine"},{"key":"291_CR56","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41541-019-0104-x","volume":"4","author":"DR Stein","year":"2019","unstructured":"Stein, D. R. et al. A recombinant vesicular stomatitis-based Lassa fever vaccine elicits rapid and long-term protection from lethal Lassa virus infection in guinea pigs. npj Vaccines 4, 1\u20137 (2019).","journal-title":"npj Vaccines"},{"key":"291_CR57","doi-asserted-by":"publisher","first-page":"5890","DOI":"10.1128\/JVI.01948-08","volume":"83","author":"S Baize","year":"2009","unstructured":"Baize, S. et al. Early and strong immune responses are associated with control of viral replication and recovery in lassa virus-infected cynomolgus monkeys. J. Virol. 83, 5890\u20135903 (2009).","journal-title":"J. Virol."},{"key":"291_CR58","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1000836","volume":"6","author":"L Flatz","year":"2010","unstructured":"Flatz, L. et al. T cell-dependence of Lassa fever pathogenesis. PLoS Pathog. 6, e1000836 (2010).","journal-title":"PLoS Pathog."},{"key":"291_CR59","doi-asserted-by":"publisher","first-page":"276","DOI":"10.3389\/fimmu.2018.00276","volume":"9","author":"E Panagioti","year":"2018","unstructured":"Panagioti, E., Klenerman, P., Lee, L. N., van der Burg, S. H. & Arens, R. Features of effective T cell-inducing vaccines against chronic viral infections. Front. Immunol. 9, 276 (2018).","journal-title":"Front. Immunol."},{"key":"291_CR60","doi-asserted-by":"publisher","first-page":"3739","DOI":"10.1016\/j.vaccine.2013.05.021","volume":"31","author":"E Van Braeckel","year":"2013","unstructured":"Van Braeckel, E. et al. Polyfunctional CD4(+) T cell responses in HIV-1-infected viral controllers compared with those in healthy recipients of an adjuvanted polyprotein HIV-1 vaccine. Vaccine 31, 3739\u20133746 (2013).","journal-title":"Vaccine"},{"key":"291_CR61","doi-asserted-by":"publisher","first-page":"8468","DOI":"10.1128\/JVI.00228-07","volume":"81","author":"S Kannanganat","year":"2007","unstructured":"Kannanganat, S., Ibegbu, C., Chennareddi, L., Robinson, H. L. & Amara, R. R. Multiple-cytokine-producing antiviral CD4 T cells are functionally superior to single-cytokine-producing cell. J. Virol. 81, 8468\u20138476 (2007).","journal-title":"J. Virol."},{"key":"291_CR62","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1053\/j.gastro.2012.06.005","volume":"143","author":"S-H Park","year":"2012","unstructured":"Park, S.-H. et al. Successful vaccination induces multifunctional memory T-cell precursors associated with early control of hepatitis C virus. Gastroenterology 143, 1048\u20131060 (2012).","journal-title":"Gastroenterology"},{"key":"291_CR63","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1038\/nm.3350","volume":"19","author":"S Sridhar","year":"2013","unstructured":"Sridhar, S. et al. Cellular immune correlates of protection against symptomatic pandemic influenza. Nat. Med. 19, 1305\u20131312 (2013).","journal-title":"Nat. Med."},{"key":"291_CR64","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.antiviral.2016.08.012","volume":"133","author":"RW Cross","year":"2016","unstructured":"Cross, R. W. et al. Treatment of Lassa virus infection in outbred guinea pigs with first-in-class human monoclonal antibodies. Antivir. Res. 133, 218\u2013222 (2016).","journal-title":"Antivir. Res."},{"key":"291_CR65","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1038\/nm.4396","volume":"23","author":"CE Mire","year":"2017","unstructured":"Mire, C. E. et al. Human-monoclonal-antibody therapy protects nonhuman primates against advanced Lassa fever. Nat. Med. 23, 1146\u20131149 (2017).","journal-title":"Nat. Med."},{"key":"291_CR66","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1016\/j.cell.2019.07.020","volume":"178","author":"KM Hastie","year":"2019","unstructured":"Hastie, K. M. et al. Convergent structures illuminate features for germline antibody binding and pan-Lassa virus neutralization. Cell 178, 1004\u20131015 (2019).","journal-title":"Cell"},{"key":"291_CR67","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-020-00219-x","volume":"5","author":"H M\u00fcller","year":"2020","unstructured":"M\u00fcller, H. et al. Adjuvant formulated virus-like particles expressing native-like forms of the Lassa virus envelope surface glycoprotein are immunogenic and induce antibodies with broadly neutralizing activity. npj Vaccines 5, 71 (2020).","journal-title":"npj Vaccines"},{"key":"291_CR68","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1002\/bit.24342","volume":"109","author":"MG Cottingham","year":"2012","unstructured":"Cottingham, M. G. et al. Preventing spontaneous genetic rearrangements in the transgene cassettes of adenovirus vectors. Biotechnol. Bioeng. 109, 719\u2013728 (2012).","journal-title":"Biotechnol. Bioeng."},{"key":"291_CR69","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1038\/nm0498-397","volume":"4","author":"J Schneider","year":"1998","unstructured":"Schneider, J. et al. Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara. Nat. Med. 4, 397\u2013402 (1998).","journal-title":"Nat. Med."},{"key":"291_CR70","doi-asserted-by":"publisher","first-page":"7264","DOI":"10.4049\/jimmunol.175.11.7264","volume":"175","author":"AC Moore","year":"2005","unstructured":"Moore, A. C. et al. Anti-CD25 antibody enhancement of vaccine-induced immunogenicity: increased durable cellular immunity with reduced immunodominance. J. Immunol. 175, 7264\u20137273 (2005).","journal-title":"J. Immunol."},{"key":"291_CR71","doi-asserted-by":"publisher","first-page":"3822","DOI":"10.1128\/JVI.02568-07","volume":"82","author":"S Sridhar","year":"2008","unstructured":"Sridhar, S. et al. Single-dose protection against Plasmodium berghei by a simian adenovirus vector using a human cytomegalovirus promoter containing intron A. J. Virol. 82, 3822\u20133833 (2008).","journal-title":"J. Virol."},{"key":"291_CR72","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1038\/nm.1850","volume":"14","author":"SJ Draper","year":"2008","unstructured":"Draper, S. J. et al. Effective induction of high-titer antibodies by viral vector vaccines. Nat. Med. 14, 819\u2013821 (2008).","journal-title":"Nat. Med."},{"key":"291_CR73","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1038\/s41564-020-0688-y","volume":"5","author":"M Letko","year":"2020","unstructured":"Letko, M., Marzi, A. & Munster, V. Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses. Nat. Microbiol. 5, 562\u2013569 (2020).","journal-title":"Nat. Microbiol."},{"key":"291_CR74","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.1016\/j.celrep.2018.07.045","volume":"24","author":"M Letko","year":"2018","unstructured":"Letko, M. et al. Adaptive evolution of MERS-CoV to species variation in DPP4. Cell Rep. 24, 1730\u20131737 (2018).","journal-title":"Cell Rep."},{"key":"291_CR75","doi-asserted-by":"crossref","unstructured":"Marzi, A. et al. Vesicular stomatitis virus-based Ebola vaccines with improved cross-protective efficacy. J. Infect. Dis. 204, S1066-74 (2011).","DOI":"10.1093\/infdis\/jir348"},{"key":"291_CR76","doi-asserted-by":"publisher","first-page":"e0003793","DOI":"10.1371\/journal.pntd.0003793","volume":"9","author":"S Nikisins","year":"2015","unstructured":"Nikisins, S. et al. International external quality assessment study for molecular detection of Lassa virus. PLoS Negl. Trop. Dis. 9, e0003793 (2015).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"291_CR77","unstructured":"Hierholzer, J. C. & Killington, R. A. in Virology Methods Manual (eds. Mahy, B. W. J. & Kangro, H. O.) 35\u201339 (Academic Press, 1996)."}],"container-title":["npj Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41541-021-00291-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-021-00291-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-021-00291-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,29]],"date-time":"2023-01-29T14:06:24Z","timestamp":1675001184000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41541-021-00291-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,2]]},"references-count":77,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["291"],"URL":"https:\/\/doi.org\/10.1038\/s41541-021-00291-x","relation":{},"ISSN":["2059-0105"],"issn-type":[{"value":"2059-0105","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,2]]},"assertion":[{"value":"29 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"S.C.G. is a board member of Vaccitech and named as an inventor on a patent covering use of ChAdOx1-vectored vaccines. S.S. is currently an employee of Vaccitech, but was employed a the University of Oxford at the time of her contribution to the work presented here. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"32"}}